OTHER GROUP COMPANIES
market

SMS Lifesciences successfully completes USFDA inspection at its API facility

The inspection commenced on 04.04.2022 and concluded on April 08, 2022, the company said.

April 12, 2022 8:57 IST | India Infoline News Service
SMS Lifesciences India on Friday has completed the United States Food and Drug Administration (USFDA) inspection at its API manufacturing facility Telangana (Unit I), without any observations.

“The Company has completed the United States Food and Drug Administration (USFDA) inspection at its API's manufacturing facility located at Sy. No.180/2, Kazipally, Jinnaram MandaI, Sangareddy district, Telangana (Unit I), without any observations,” the company said in the filing.

The inspection commenced on 04.04.2022 and concluded on April 08, 2022.

The stock is currently trading at Rs840.70 down by Rs34.25 or 3.91% from its previous closing of Rs874.95 on the BSE. The scrip opened at Rs869 and has touched a high and low of Rs869 and Rs828.95 respectively.

OPEN A DEMAT ACCOUNT & Get
FREE Benefits Worth 5,000

FEATURED ARTICLE

BLOGS

Open Demat Account

  • 0

    Per Order for ETF & Mutual Funds Brokerage

  • 20

    Per Order for Delivery, Intraday, F&O, Currency & Commodity